Safety and Efficacy of DA-9805 for Parkinson's Disease
Status:
Completed
Trial end date:
2019-04-10
Target enrollment:
Participant gender:
Summary
This is a phase IIa, first in human, randomized, double-blind, multicenter study to evaluate
the safety, tolerability and efficacy of DA-9805 at 45mg, 90mg versus placebo in subjects
diagnosed with early Parkinson's disease.